Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
C1QL3 Biologics Sequence Review Report 2026: Complement C1q-like protein 3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
C1QL3 Biologics Sequence Review Report 2026: Complement C1q-like protein 3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of C1QL3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
C1QB Biologics Sequence Review Report 2026: Complement C1q subcomponent subunit B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
C1QB Biologics Sequence Review Report 2026: Complement C1q subcomponent subunit B Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of C1QB protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
C1QC Biologics Sequence Review Report 2026: Complement C1q subcomponent subunit C Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
C1QC Biologics Sequence Review Report 2026: Complement C1q subcomponent subunit C Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of C1QC protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BRS3 Biologics Sequence Review Report 2026: Bombesin receptor subtype-3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BRS3 Biologics Sequence Review Report 2026: Bombesin receptor subtype-3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of BRS3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
C1QA Biologics Sequence Review Report 2026: Complement C1q subcomponent subunit A Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
C1QA Biologics Sequence Review Report 2026: Complement C1q subcomponent subunit A Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of C1QA protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BUB3 Biologics Sequence Review Report 2026: Mitotic checkpoint protein BUB3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BUB3 Biologics Sequence Review Report 2026: Mitotic checkpoint protein BUB3 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of BUB3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BST2 Biologics Sequence Review Report 2026: Bone marrow stromal antigen 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BST2 Biologics Sequence Review Report 2026: Bone marrow stromal antigen 2 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of BST2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BCAP31 Biologics Sequence Review Report 2026: B-cell receptor-associated protein 31 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BCAP31 Biologics Sequence Review Report 2026: B-cell receptor-associated protein 31 Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of BCAP31 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BIVM Biologics Sequence Review Report 2026: Basic immunoglobulin-like variable motif-containing protein Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BIVM Biologics Sequence Review Report 2026: Basic immunoglobulin-like variable motif-containing protein Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of BIVM protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BDKRB2 Biologics Sequence Review Report 2026: B2 bradykinin receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BDKRB2 Biologics Sequence Review Report 2026: B2 bradykinin receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of BDKRB2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
BDKRB1 Biologics Sequence Review Report 2026: B1 bradykinin receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
BDKRB1 Biologics Sequence Review Report 2026: B1 bradykinin receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of BDKRB1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
AVPR2 Biologics Sequence Review Report 2026: Vasopressin V2 receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
AVPR2 Biologics Sequence Review Report 2026: Vasopressin V2 receptor Similarity and Patent-Risk Signals
14 August 2026
A Biology Modality MCP review of AVPR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →